16 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
9 May 24
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
4:14pm
of presentations highlights Biohaven's leadership in neuroscience and immunoscience as well as extensive development programs evaluating novel therapies
8-K
EX-99.1
BHVN
Biohaven Ltd.
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
not have advanced the SCA program this far without the leadership from the National Ataxia Foundation that has supported basic science research as well
8-K
EX-99.1
BHVN
Biohaven Ltd.
12 May 23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
4:47pm
to normal IgA, in an endocytosis assay with HepG2 cells.
Leadership team expanded with key appointment - In April 2023, Biohaven announced the appointment
8-K
EX-99.1
au7t2 j7soi5t
9 Nov 22
Biohaven LTD. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
4:05pm
424B4
cwa76rg
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
ql9y75qr8 qz34ai7
20 Oct 22
IPO registration (amended)
10:00am
S-1
trw4s0zvyz5eli
18 Oct 22
IPO registration
4:03pm
DRS
1cy wx2ujokz3lxlq4
11 Oct 22
Draft registration statement
12:00am
10-12B/A
EX-99.1
t98eq dhu387ercfnfvu
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
q9qxa itlb
14 Sep 22
Registration of securities (amended)
5:25pm
10-12B/A
EX-99.1
x7jjvh3ebvhku
7 Sep 22
Registration of securities (amended)
7:26am
10-12B/A
EX-99.1
wpvpay8
24 Aug 22
Registration of securities (amended)
5:03pm
10-12B
EX-99.1
twc0qkove4lzytvq
10 Aug 22
Registration of securities
5:07pm
DRS
EX-99.1
hu0kn y7n0
1 Jul 22
Draft registration statement
12:00am
- Prev
- 1
- Next